E.g., 06/13/2021
E.g., 06/13/2021
Title Category Credit Event Date Price
Update Series Volume 39 (2020)
    • 40.00 AMA PRA Category 1 Credit™
    • 40.00 Non-Physician Participation
$480.00 New for 2020! Audio Lessons - Listen on-the-go!Access audio recordings of all 40 lessons to conveniently stream the material on-the-go! Audio Lessons will be released in coordination with their online companion lessons.Listen now and tell us what you think!
Update Series Volume 40 (2021)
    • 40.00 AMA PRA Category 1 Credit™
    • 40.00 Non-Physician Participation
$480.00
Using Shared Decision Making to Help Patients Decide on Prostate Cancer Screening and Treatment Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 This course teaches the essentials of Shared Decision Making (SDM) to practicing urologists who help patients decide about prostate cancer screening and treatment. The course will go over the latest research documenting the benefits and drawbacks of PSA screening as well as treatment approaches for incident localized prostate cancer. It will also teach the participants how to practice SDM with their patients and will engage them in group-based role play.
What's New in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 This course will include case-based presentations and ARS in three distinct diseases groups: hormone-sensitive metastatic prostate cancer (HSMPC); non-metastatic castrate resistant prostate cancer (M0CRPC) and metastatic CRPC (MCRPC) to educate urologists, APP's and their teams to identify and understand the many new FDA-approved agents, as well as existing standard therapies. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed.

Pages